Evidence map›Paper›PMID 40220121›Full record

ArticleStem cell reviews and reports2025

Attenuation of Cellular Senescence and Improvement of Osteogenic Differentiation Capacity of Human Liver Stem Cells Using Specific Senomorphic and Senolytic Agents.

Allancer D C Nunes, Louise E Pitcher, Henry A Exner, Diego J Grassi, Brittan Burns, Maria Beatriz Herrera Sanchez, Ciro Tetta, Giovanni Camussi, Paul D Robbins

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Stem cell reviews and reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Allancer D C NunesMasonic Institute on the Biology of Aging and Metabolism, University of Minnesota, Minneapolis, Minnesota, USA.
Louise E PitcherMasonic Institute on the Biology of Aging and Metabolism, University of Minnesota, Minneapolis, Minnesota, USA.
Henry A ExnerMasonic Institute on the Biology of Aging and Metabolism, University of Minnesota, Minneapolis, Minnesota, USA.
Diego J GrassiAelis Farma, Bordeaux, France.
Brittan BurnsMasonic Institute on the Biology of Aging and Metabolism, University of Minnesota, Minneapolis, Minnesota, USA.
Maria Beatriz Herrera SanchezMolecular Biotechnology Centre, University of Torino, Torino, Italy.
Ciro TettaUnicyte AG, Oberdorf, Switzerland.
Giovanni CamussiMolecular Biotechnology Centre, University of Torino, Torino, Italy.
Paul D RobbinsMasonic Institute on the Biology of Aging and Metabolism, University of Minnesota, Minneapolis, Minnesota, USA. probbins@umn.edu.ORCID 0000-0003-1068-7099

Funding

Targeting Cellular Senescence to Extend HealthspanP01AG062413 · NIA · MAYO CLINIC ROCHESTER · PI Sundeep Khosla, Nathan K LeBrasseur · 2019 to 2026
$28.7M
Validation and characterization of the identified variants associated with human longevity in mouse modelsU19AG056278 · NIA · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI JAN VIJG · 2017 to 2026
$24.5M
Midwest Murine-Tissue Mapping Center (MM-TMC)U54AG079754 · NIA · UNIVERSITY OF MINNESOTA · PI GR Scott Budinger, Sundeep Khosla · 2022 to 2026
$11.5M
Minnesota Tissue Mapping Center for Senescent CellsU54AG076041 · NIA · UNIVERSITY OF MINNESOTA · PI Constantin F. Aliferis, LAURA Jane NIEDERNHOFER · 2021 to 2026
$10.5M
Using the senolytic fisetin to suppress mortality in aged mice acutely exposed to murine beta-coronavirusR01AG063543 · NIA · UNIVERSITY OF MINNESOTA · PI NIEDERNHOFER, LAURA JANE · 2019 to 2023
$3.4M
Inflammation, Lipid Metabolism and SenescenceR01AG069819 · NIA · UNIVERSITY OF MINNESOTA · PI CAMELL, CHRISTINA · 2020 to 2024
$1.9M
NIA NIH HHS P01 AG062413NIA NIH HHS R01 AG063543NIA NIH HHS R01 AG069819NIA NIH HHS U19 AG056278NIA NIH HHS U54 AG076041NIA NIH HHS U54 AG079754NIH HHS P01 AG062413NIH HHS R01 AG063543NIH HHS R01 AG069819NIH HHS U19 AG056278NIH HHS U54 AG076041NIH HHS U54 AG079754Regione Piemonte POR FESR 2014/2020
6 · The paper itself

Abstract

Expansion of adult stem cells in culture increases the percent of senescent cells, reduces their differentiation capacity and limits their clinical use. Here, we investigated whether treatment with certain senotherapeutic drugs would reduce the accumulation of senescent cells during expansion of human liver stem cells (HLSCs) while maintaining their differentiation capacity. Our results demonstrate that chronic treatment with the senomorphic XJB-5-131 or the senolytics cocktail D + Q reduced the number of senescent cells and significantly reduced the expression of senescence-associated genes and several inflammatory SASP factors in later passage HLSCs. Additionally, treatment with XJB-5-131 and D + Q improved the capacity of HLSCs to undergo osteogenic differentiation following extensive in vitro expansion. Overall, our data demonstrate that treatment with XJB-5-13 or D + Q results in a reduction in the percentage of replication-induced senescent HLSCs and likely other types of adult stem cells and improve the potential therapeutic use of later passage human stem cells.

Indexed as

Cell DifferentiationCellular SenescenceLiverOsteogenesisSenotherapeuticsStem CellsCell ProliferationCells, CulturedHumansSenotherapeuticsCellular senescenceHuman liver stem cellsOsteogenic differentiationSenotherapeutics

Identifiers

PMID40220121
PMCPMC12316771

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.